Table 2.
Analyses of risk factors for tumor recurrence after liver transplantation in all 26 patients with intrahepatic tumor dissemination and macrovascular invasion included in the study.
| Factors | HR (95% CI) | p |
|---|---|---|
| Male sex | 0.62 (0.12–3.15) | 0.560 |
| Age | 0.99 (0.91–1.09) | 0.886 |
| MELD | 1.04 (0.94–1.14) | 0.437 |
| HBV infection | 3.84 (1.08–13.64) | 0.038 |
| HCV infection | 0.70 (0.18–2.83) | 0.622 |
| ALD | 1.02 (0.26–3.93) | 0.979 |
| AFP model | 1.45 (1.09–1.94) | 0.001 |
| Tumor number | 1.15 (0.89–1.48) | 0.274 |
| Tumor size | 1.40 (0.92–2.11) | 0.113 |
| Alpha-fetoprotein | 1.06 (0.87–1.29) | 0.552 |
| Ca 19-9 | 0.83 (0.32–2.19) | 0.710 |
| Poor tumor differentiation | 4.09 (0.90–18.47) | 0.067 |
| Microvascular invasion | 0.58 (0.16–2.12) | 0.414 |
| Macrovascular invasion | 1.02 (0.27–3.81) | 0.977 |
| Neoadjuvant treatment | 0.89 (0.23–3.45) | 0.868 |
| Total ischemic time | 1.94 (1.23–3.05) | 0.004 |
| Donor age | 0.94 (0.89–0.99) | 0.016 |
| Male donor sex | 0.89 (0.27–2.95) | 0.855 |
| Intraoperative PRBC transfusions (units) | 1.14 (0.96–1.35) | 0.127 |
| Intraoperative FFP transfusions (units) | 1.09 (0.92–1.30) | 0.301 |
Hazard ratios are for quantitative variables were given per: 1 year increase for recipient and donor age; 1 point increase for MELD; 1 increase for tumor number; 1 cm increase for tumor size; 1 loge increase for alpha-fetoprotein and Ca 19-9; 1 h increase for total ischemic time; 1 unit increase for transfusions. HR = hazard ratio; 95% CI = 95% confidence interval; MELD = model for end-stage liver disease; HBV = hepatitis B virus; HCV = hepatitis C virus; ALD = alcoholic liver disease; PRBC = packed red blood cells; FFP = fresh frozen plasma.